Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Shanks

Neurological Surgery Frisco, TX Medical Doctor

NPI 1154542181 CMS profile 279793

11500 State Highway 121 Ste 1010, Frisco, TX 75035

Open in the dashboard

General payments

$166,969

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Todd Shanks of Frisco, TX is reported in the CMS Open Payments database as having received $166,969 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,067 15
2024 General $762 7
2023 General $1,024 15
2022 General $97,830 19
2021 General $37,540 35
2020 General $5,473 30
2019 General $16,275 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Shanks
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Todd Shanks were reported at $8,067. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Todd Shanks Neurological Surgery median Middle half National median
2019 $16,275 $582 $138–$3,006 $163
2020 $5,473 $294 $76–$2,174 $114
2021 $37,540 $387 $105–$2,432 $132
2022 $97,830 $542 $139–$2,989 $149
2023 $1,024 $534 $145–$2,697 $160
2024 $762 $574 $155–$3,046 $164
2025 $8,067 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Republic Spine, LLC $132,053 20 payments
  2. Innovasis Inc $20,206 24 payments
  3. HD LifeSciences LLC $7,716 4 payments
  4. Abbott Laboratories $1,696 31 payments
  5. 4WEB, Inc. $1,000 1 payment
  6. Camber Spine Technologies $956 15 payments
  7. The Institute of Musculoskeletal Science and Education $530 1 payment
  8. icotec Medical Inc. $463 5 payments
  9. Medtronic USA, Inc. $447 12 payments
  10. Medtronic, Inc. $380 7 payments
  11. Other $1,523 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $139,000 17 payments
  2. Royalty or License $11,755 2 payments
  3. Travel and Lodging $8,179 9 payments
  4. Food and Beverage $7,505 122 payments
  5. Gift $530 1 payment
Products named General payments · program years 2019–2025
  1. Expandable Interbody System $131,250 15 payments
  2. Hive ALIF, Hive O-AL, $6,750 1 payment
  3. SPINE TRUSS SYSTEM $1,000 1 payment
  4. Hive O-AL $648 1 payment
  5. Proclaim Family of SCS IPGs $447 4 payments
  6. Penta SCS Leads $327 11 payments
  7. 7D Surgical System $287 2 payments
  8. Hive ALIF, Hive O-AL, Hive Standalone Cervical $253 1 payment
  9. TiLock $242 2 payments
  10. PROCLAIM $201 2 payments
  11. Other $3,271 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

147

Median for Neurosurgery: 83

Drug cost

$2,416

Median for Neurosurgery: $872

Branded share of claims

18.4%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 39 $1,086
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $630
Gabapentin Generic 55 $491
Methylprednisolone Generic 26 $208

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$63,543

Medicare's payments for the services billed

Medicare patients

81

Average age 74

Services billed

237

34 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 35%
Chronic kidney disease 27%
Atrial fibrillation 26%
Osteoporosis 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record